Ϫ7 M fenoterol induced sensitization characterized by an increase in maximal contraction to endothelin-1 (ET-1) and acetylcholine (ACh). Incubation of human bronchi with 10 Ϫ6 , 3 ϫ 10 Ϫ6 , and 10 Ϫ5 M forskolin (an adenyl cyclase activator) reproduced sensitization to ET-1 and ACh. The sensitizing effect of fenoterol was inhibited by coincubation with gliotoxine (a nuclear factor-B inhibitor), dexamethasone, indomethacin (a cyclooxygenase inhibitor), GR-32191 (a TP prostanoid receptor antagonist), MK-476 (a cysteinyl leukotriene type 1 receptor antagonist), SR-140333 ϩ SR-48968 ϩ SR-142801 (neurokinin types 1, 2, and 3 tachykinin receptor antagonists) with or without HOE-140 (a bradykinin B 2 receptor antagonist), SB-203580 (an inhibitor of the 38-kDa mitogen-activated protein kinase, p38 MAPK ), or calphostin C (a protein kinase C blocker). Our results suggest that chronic exposure to fenoterol induces proinflammatory effects mediated by nuclear factor-B and pathways involving leukotrienes, prostanoids, bradykinin, tachykinins, protein kinase C, and p38 MAPK , leading to the regulation of smooth muscle contraction to ET-1 and ACh.
THE FATAL ACUTE ASTHMA CASES attributable to fenoterol abuse in the 1980s in New Zealand started a controversy concerning the potential worsening of the bronchial hyperresponsiveness by the ␤ 2 -adrenoceptor agonists (7, 14, 42) . Studies in animals and humans showed that chronic exposure to fenoterol or salbutamol induces a nonspecific bronchial sensitization, whereas the relaxant effects of these ␤ 2 -agonists on the airway smooth muscle are not decreased (11, 59, 60) . The bronchial sensitization induced by fenoterol is similar to the sensitization provoked by ovalbumin in sensitized guinea pigs (60) . Chronic administration of salbutamol at low doses to guinea pigs increases airway reactivity to histamine and methacholine (11) . In humans, long-term use of salbutamol increases the bronchial hyperresponsiveness to histamine but does not cause subsensitization of ␤ 2 -adrenoceptors to salbutamol (59) . In a bovine tracheal model, Katsunuma and colleagues (36) showed that prolonged incubation with fenoterol induced an increased contractile responsiveness to neurokinin A (NKA). In 1995, Peters and colleagues (47) suggested that the continuous activation of the intracellular signal transduction caused by the ␤ 2 -adrenoceptor stimulation could induce a proinflammatory process mediated by nuclear transcription factors in rat lung. A recent study in our institution showed that the transcription factor nuclear factor-B (NF-B) is involved in fenoterol-induced hyperresponsiveness to NKA in guinea pig isolated trachea (52) .
Endothelin-1 (ET-1) is a 21-amino acid peptide recently implicated in chronic inflammatory airway diseases such as asthma and chronic obstructive pulmonary disease (25, 26, 41, 46) . ET-1 is synthesized and metabolized in lung, and ET-1 receptors (ET A and ET B ) are widely distributed in airway cells (21, 26, 41) . ET-1 is one of the most potent contractile agents of human airway smooth muscle and can induce airway inflammation, airway hyperresponsiveness, and airway remodeling in animals and humans (25, 26, 27, 41) , suggesting that ET-1 could be a major component of asthma pathophysiology (10, 22, 26, 27) . The purpose of this study was to determine the sensitizing effect of fenoterol on the contraction to ET-1 of human bronchi and to investigate the role of inflammatory mediators and signal transduction pathways involved in airway sensitization to ET-1 induced by ␤ 2 -adrenoceptor agonists.
METHODS
Human bronchial tissue preparations. Bronchial tissues were surgically removed from 54 patients with lung cancer (45 men and 9 women, 62 Ϯ 10 yr of age); all patients were smokers or ex-smokers. Just after resection, segments of human bronchi (1-3 mm ID) were taken as far as possible from the malignant lesion. They were placed in oxygenated Krebs-Henseleit solution composed of (in mM) 119 NaCl, 4.7 KCl, 2. Ϫ7 M), 9) an inhibitor of the 38-kDa mitogen-activated protein kinase (MAPK), SB-203580, 10) a protein kinase C (PKC) blocker, calphostin C (10 Ϫ7 M), and 11) SB-203580 ϩ calphostin C. Because SB-203580 has been shown to inhibit COX-1 and COX-2, on the one hand, and thromboxane synthase, on the other hand, with IC50 for both enzymes of 2 ϫ 10 Ϫ6 M in human platelets (9) and 1.8 ϫ 10 Ϫ6 M in human airway smooth muscle (24) , we studied in preliminary experiments the potential inhibitory effect of SB-203580, calphostin C, and SB-203580 ϩ calphostin C on the contraction of human bronchus induced by [Sar 9 ,Met(O2) 11 ]substance P (10 Ϫ7 M), which acts in part through the COX and thromboxane synthase pathway (4) . Moreover, we used 10 Ϫ7 M calphostin C according to Barman (5) . To investigate the mechanisms of change in airway contractility after sensitization by fenoterol, we conducted a second protocol, where drugs (10
Ϫ7 M SR-140333, 10 Ϫ7 M SR-48968, 10 Ϫ7 M SR-142801, and 10 Ϫ7 M HOE-140) were added, after 15 h of incubation at room temperature with 10 Ϫ7 M fenoterol, to the organ bath at 37°C 45 min before addition of ET-1 and ACh.
Experimental procedure. After incubation with drugs, the bronchial rings were suspended on hooks in a 5-ml organ bath containing Krebs-Henseleit solution, gassed with 95% O2-5% CO2 and maintained at 37°C. Each preparation was connected to a force displacement transducer (model UF1, Statham), and isometric tension changes were recorded on a polygraph. Preparations were suspended with an initial tension of 1.5 g in organ baths and equilibrated for 60 min, with changes in fresh Krebs-Henseleit solution every 10 min during the first 30 min of the equilibrium period before the start of data acquisition. A load of 1-1.5 g was maintained throughout the first 30 min of the equilibrium period. Concentration-response curves to ET-1 (10 Ϫ10 -10 Ϫ7 M with logarithmic increments) were then obtained by applying increasing concentrations at 10-to 15-min intervals. Only one concentration-response curve was recorded for each ring. Then human bronchi were maximally contracted with 3 ϫ 10 Ϫ3 M ACh. Previous exposure of human bronchus to ET-1 has no effect on contraction induced by exogenous ACh (17) .
Drugs. 50 values were derived graphically from the logarithmic concentration-effect curves and defined as the negative logarithm of the drug concentration that caused 50% of maximal effect of ET-1 (10 Ϫ7 M). ⌬(Ϫlog EC50) represents the difference between Ϫlog EC 50 obtained with the pretreated bronchi and Ϫlog EC 50 obtained with the paired control human bronchi. Bronchi with E max of ET-1 Ͻ0.7 g were excluded from analysis, because we considered that a low level of E max is a reliable marker of dysfunction of contractility. Statistical analysis of the results was performed using Student's t-test (2-tailed, for paired samples). P Ͻ 0.05 was considered significant.
RESULTS
Sample. Bronchi of 48 from 54 patients (89%) yielded an E max of ET-1 Ն0.7 g. Incubation of these 48 bronchi for 15 h at 21°C with fenoterol (10 Ϫ7 M) significantly increased their maximal contraction to ET-1 ( Fig. 1) and ACh (E max of ACh ϭ 2.66 Ϯ 0.18 and 1.99 Ϯ 0.15 g in the presence and absence of fenoterol, respectively, n ϭ 48, P Ͻ 0.01). Incubation of human bronchi with fenoterol did not change significantly the potency of ET-1 (Ϫlog EC 50 ϭ 8.52 Ϯ 0.05 and 8.41 Ϯ 0.06 in the presence and absence of fenoterol, respectively, n ϭ 48, not significant; Fig. 1 ). Because sensitization of human bronchi by fenoterol was characterized by an increase in maximal contraction to ET-1, we investigated the human bronchi with ⌬E max of ET-1 Ͼ0 after 15 h of fenoterol exposure. Among the 48 bronchi, 38 (79%) presented a ⌬E max of ET-1 Ͼ0. Analysis of data was performed from this sample of 38 human bronchi. M) was added to the incubation medium of bronchi ( Table 1) . Potency of ET-1 (Ϫlog EC 50 ) was not significantly modified by incubation with these drugs (Table  1) . Forskolin, a cAMP activator, increased the maximal contraction to ET-1 and ACh in a concentration-dependent manner (Table 1) . Incubation with forskolin (10
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, 3 ϫ 10
, and 10 Ϫ5 M) had no significant effect on potency of ET-1 ( Table 1) . Figs. 2 and 3) . Incubation with L-NAME or SR-142801 had no significant effect on the sensitization induced by fenoterol (Fig. 2) . Addition of HOE-140 to SR-140333 ϩ SR-48968 ϩ SR-142801 did not significantly increase the inhibition of SR-140333 ϩ SR-48968 ϩ SR-142801 on the fenoterol-induced sensitizing effect (Fig. 3) .
Effect of incubation with anti-inflammatory drugs
Effect of coincubation with MAPK inhibitor, PKC blocker, and MAPK inhibitor ϩ PKC blocker on fenoterol-induced sensitization. In preliminary experiments, we found that 10 Ϫ6 M, but not 10 Ϫ7 and 3 ϫ 10 Ϫ7 M, SB-203580 inhibited the contraction of nine human bronchi induced by [Sar 9 ,Met(O 2 ) 11 ]substance P, which Values are means Ϯ SE; n, number of bronchi. Bronchi were pretreated for 15 h at 21°C. ⌬(Ϫlog EC50), difference between Ϫlog EC50 (potency) obtained with pretreated bronchi and Ϫlog EC50 obtained with paired control human bronchi; ⌬Emax, difference between maximal contraction (maximal efficacy) to endothelin-1 (ET-1) and-to acetylcholine (ACh) in pretreated bronchi and in paired control; * P Ͻ 0.05; † P Ͻ 0.01; ‡ P Ͻ 0.001 vs. control. acts through the COX and thromboxane synthase pathway (Table 3) . Therefore, we used Ͻ10 Ϫ6 M SB-203580 (i.e., 10 Ϫ7 and 3 ϫ 10 Ϫ7 M). In control experiments (absence of fenoterol), 15 h of incubation at 21°C with the inhibitor of p38 MAPK SB-203580 (10 Ϫ7 M) alone and the PKC blocker calphostin C (10 Ϫ7 M) had no significant effect on the E max of ET-1 and ACh ( Table 2) . Addition of SB-203580 (3 ϫ 10 Ϫ7 M) to calphostin C (10 Ϫ7 M) did not modify significantly the E max of ET-1 and ACh (Table 2) . When the same paired bronchi were sensitized to ET-1 and ACh by fenoterol for 15 h at 21°C (control bars, Fig. 4) , coincubation with SB-203580 (10 Ϫ7 and 3 ϫ 10 Ϫ7 M), calphostin C (10 Ϫ7 M), or calphostin C ϩ SB-203580 significantly decreased the rise of maximal response induced by fenoterol (Fig. 4) .
Effects of the anti-inflammatory drugs, the proinflammatory mediator receptor antagonists, or an NOS inhibitor on maximal contraction to ET-1 and ACh after sensitization by fenoterol.
In control experiments (absence of fenoterol), 45 min of incubation at 37°C Values are means Ϯ SE; n, number of bronchi. Bronchi were pretreated for 15 h at 21°C. Gliotoxine, nuclear factor-B inhibitor; GR-32191; prostanoid and prostaglandin TP receptor antagonist; MK-476, cysteinyl leukotriene receptor antagonist; L-NAME, N-nitro-L-arginine methyl ester, a nitric oxide (NO) synthase inhibitor; SR-14033, SR-48968, and SR 142801, tachykinin NK1, NK2, and NK3 receptor antagonists; HOE-140, bradykinin B2 receptor antagonist; SB-203580, 38-kDa mitogen-activated protein kinase inhibitor; calphostin C, protein kinase C blocker. No difference was statistically significant. with L-NAME (10 Ϫ3 M) increased significantly the maximal contraction to ET-1 and ACh (Table 4) . Incubation for 45 min at 37°C with indomethacin, GR-32191, MK-476, or combinations of the tachykinin NK 1 ϩ NK 2 ϩ NK 3 receptor antagonists did not alter the maximal contraction of the human bronchi (Table  4) . Addition of HOE-140, a bradykinin B 2 receptor antagonist, to the tachykinin NK 1 ϩ NK 2 ϩ NK 3 receptor antagonists did not modify the E max of ET-1 and ACh of the bronchi (Table 4) . When the same paired bronchi were sensitized to ET-1 and ACh by fenoterol for 15 h at 21°C (control bars, Fig. 5 ), incubation for 45 min at 37°C with indomethacin, GR-32191, MK-476, and L-NAME did not affect the sensitizing effect induced by fenoterol (Fig. 5) . In contrast, incubation for 45 min at 37°C with SR-140333 ϩ SR-48968 ϩ SR-142801 or SR-140333 ϩ SR-48968 ϩ SR-142801 ϩ HOE-140 significantly decreased the rise of the maximal response elicited by fenoterol (Fig. 6) . Addition of HOE-140 to SR-140333 ϩ SR-48968 ϩ SR-142801 did not significantly increase the inhibition of SR-140333 ϩ SR-48968 ϩ SR-142801 on the sensitizing effect induced by fenoterol.
DISCUSSION
In this study, we observed an in vitro sensitization to ET-1 and ACh of human bronchi by fenoterol. This sensitization is not specific to fenoterol, inasmuch as we found the same phenomenon with formoterol, salbutamol, and salmeterol. We then investigated the transduction pathways involved in sensitization of human bronchi by ␤ 2 -adrenoceptor agonists and showed Values are means Ϯ SE; n, number of bronchi. Bronchi were pretreated for 45 min at 37°C. * P Ͻ 0.05 vs. control. MAPK play a pivotal role in this event. Furthermore, several inflammatory processes appear to be involved in the sensitization of human bronchi by fenoterol.
Sensitization of human bronchi is not limited to fenoterol but is also observed with several ␤ 2 -adrenoceptor agonists in a range of concentrations known to cause submaximal relaxation (45) . We found that prolonged exposure of human bronchi to fenoterol affects maximal efficacy of ET-1 but not its potency. Our results are in agreement with the work reported by Wang and colleagues (60) , who showed that chronic fenoterol exposure increased maximal airway response to ACh but not ACh EC 50 in guinea pigs. Potency of an agonist depends in part on the affinity of receptors for binding the agonist and in part on the efficiency with which agonist-receptor interaction is coupled to response. Maximal efficacy of an agonist is determined by the characteristics of the receptor-effector system involved. In this way, our results suggest that chronic exposure to ␤ 2 -adrenoceptor agonists involves changes in the contractile proteins of human bronchi but does not alter affinity of the receptors for ET-1. In addition, forskolin, a cAMP activator, increased the maximal response to ET-1 and ACh of human bronchi in a concentration-dependent manner. This suggests that prolonged activation of the cAMP-protein kinase A (PKA) system could cause sensitization. Indeed, prolonged activation of cAMP-PKA may induce stimulation of proinflammatory nuclear transcription factors, such as NF-B or AP-1 (1, 33) , and may enhance the expression of several types of receptors, such as bradykinin B 1 and B 2 and NK 1 and NK 2 receptors implied in nonspecific airway hyperresponsiveness in animals and humans (23, 32, 36, 52) . However, short-term activation of the cAMP-PKA system may decrease the activity of proinflammatory enzymes such as constitutive phospholipase A 2 (cPLA 2 ), COX-2, 5-lipoxygenase, and MAPK (38, 54, 57) . Eickelberg and colleagues (16) showed that incubation with salmeterol or salbutamol induced, probably via calmodulin stimulation, a ligand-independent activation of the glucocorticoid receptor in cultured human lung fibroblasts and vascular smooth muscle cells. Our results conflict with these findings, but it is not well known whether inflammatory processes may regulate activation of the glucocorticoid receptor in human bronchus. In asthma, various studies underlined that long-acting ␤ 2 -adrenoceptor agonists exhibit very small, if any, anti-inflammatory effects when given alone (37).
Katsunuma and colleagues (36) showed that dexamethasone and cycloheximide (a protein synthesis blocker) inhibited the increased bovine tracheal smooth muscle contractile response to NKA induced by fenoterol. Saulnier and colleagues (52) abolished the fenoterol-induced tracheal sensitization in guinea pigs with two transcription factor NF-B inhibitors (gliotoxine and pyrrolidine dithiocarbamate). In agreement with these authors, we found that gliotoxine (an NF-B inhibitor) and dexamethasone (an NF-B and AP-1 inhibitor) abolished the sensitization induced by fenoterol in human bronchi. These results underline the pivotal role played by NF-B in the process of sensitization. NF-B is involved in the expression of proinflammatory molecules and mediators (cPLA 2 , COX-2, prostanoids, and leukotrienes) implicated in cellular events in asthma (2, 4, 6, 13). Effects of ␤ 2 -adrenoceptor agonists on NF-B pathways are not well known in humans. Korn and colleagues (39) recently showed that expression of interleukin-8, a proinflammatory cytokine stimulated in part by NF-B, was markedly increased by formoterol (10 Ϫ10 M) in cultured human bronchial epithelial cells. In contrast, Wilson and colleagues (62) observed a reduction of NF-B expression in mucosal eosinophils and epithelial cells in bronchial biopsies from 10 atopic asthmatic patients after 8 wk of treatment with formoterol. In this study, formoterol did not reduce the immunoreactivity for adhesion molecules and proinflammatory cytokines stimulated by NF-B, in contrast to glucocorticosteroid treatment. We found that indomethacin, GR-32191, and MK-476 significantly decreased or abolished the sensitization induced by fenoterol, suggesting that prolonged activation of the cAMP-PKA system by fenoterol may induce an enzymatic inflammatory process (cPLA 2 and COX-2) mediated by NF-B.
We established that a mixture of tachykinin NK 1 , NK 2 , and NK 3 receptor antagonists decreased the sensitization elicited by fenoterol. In contrast to results obtained previously in the guinea pig trachea by Saulnier and colleagues (52), we found that the NK 3 receptor antagonist SR-142801, when used alone, did not significantly reduce the fenoterol-induced sensitization. NK 3 receptors seem to be involved in airway sensitization in guinea pigs (43) , but its role is not well known in humans. However, SR-142801 has been shown to inhibit interleukin-1␤-induced hyperresponsiveness to [Sar 9 ,Met(O 2 ) 11 ]substance P (4) and nerve growth factor in human bronchi (19) . Also, our results suggest that the tachykinin NK 1 and NK 2 receptor agonists are involved in the mechanisms of sensitiza- tion of human bronchi by fenoterol. This is in agreement with the recent works reported by Katsunuma and colleagues (35, 36) , who found an increase of NK 2 receptor expression in bovine tracheal smooth muscle after treatment with fenoterol.
Leukotrienes could amplify neurogenic inflammation by increasing release of the tachykinins from the C-fibers of the nonadrenergic noncholinergic system in asthma (28) . We found that the bradykinin B 2 receptor antagonist HOE-140 did not significantly enhance the inhibition of the fenoterol-induced sensitization by the tachykinin NK 1 , NK 2 , and NK 3 receptor antagonists. Ricciardolo and colleagues (49) showed that a combination of the NK 1 and NK 2 tachykinin receptor antagonists abolished the increased bronchoconstriction produced by NKA and inhibited partially the contractile response induced by bradykinin in ovalbumin-sensitized guinea pigs, whereas HOE-140 had no effect on the increase in bronchoconstriction produced by NKA, suggesting that bradykinin induces the release of tachykinins from sensory nerves in guinea pig airways. Moreover, bradykinin may stimulate the MAPK pathways via the activation of the protein Rho GTPase, PKC, and NF-B in human lung (29) . Also, our study highlights the role of NF-B, leukotrienes, prostanoids, tachykinin NK 1 and NK 2 receptor agonists, and bradykinin in the mechanisms of sensitization of human bronchi by fenoterol (Fig. 7) .
Our results also show that SB-203580, a p38 MAPK inhibitor, at a concentration that did not inhibit COX-1 or COX-2 activity and thromboxane synthesis (Table  3) , abolishes the sensitization elicited by fenoterol. Recent studies underline the role of the MAPK in the intracellular processes of airway smooth muscle proliferation and sensitization (2, 30, 32, 46, 58, 61 (12, 23, 32, 53) . Moreover, MAPK increases the G i protein activity, which results in a functional uncoupling between G s protein and ␤ 2 -adrenoceptor (2, 32, 37) . In addition, MAPK enhances the myosin light chain kinase activity and the heavy chain of myosin expression (32) and may increase smooth muscle contraction probably via h-caldesmon phosphorylation and actin-F remodeling (30) . Interestingly, prostanoids such as thromboxane A 2 stimulate the MAPK by coupling the TP receptor with G␣ q (activation of PKC) or G i ␤␥ proteins (2, 32, 34) , and leukotrienes increase the MAPK expression in humans (48, 49) . These data suggest that MAPK pathways could amplify the inflammatory processes induced by NF-B and could sensitize the airway smooth muscle after prolonged exposure to fenoterol (Fig. 7) .
PKC is a cyclic nucleotide-independent protein kinase implicated in regulation of airway smooth muscle tone (61) . PKC-enhances the activity of the protein Raf-1 and NF-B, which activate the p38 MAPK and SAPK/JNK pathways (12) . Recent publications showed that bradykinin and thromboxane A 2 activate MAPK pathways via PKC-dependent G i ␣ protein coupling in human cells (20, 29) . In addition, PKC may increase the contractility of the airway smooth muscle by inhibiting caldesmon (via the MAPK pathways) and calponin (directly), which are involved in modulation of the actin-myosin interaction (30, 61) . We show here that blockage of PKC by calphostin C effectively inhibits fenoterol-induced sensitization. Thus our results suggest that PKC plays a major role in the intracellular mechanisms leading to fenoterol-induced sensitization of human airway smooth muscle (Fig. 7) .
We also investigated the mechanisms involved in the increase of the contractility to ET-1 and ACh of human bronchi after sensitization by fenoterol in a protocol where drugs were added after incubation with fenoterol but 45 min before addition of ET-1 or ACh at 37°C for contraction. Our results showed that neither prostanoids nor leukotrienes were involved in this mechanism. In contrast, the NK 1 , NK 2 , and NK 3 receptors appeared to be implicated in the increase of contractility after sensitization by fenoterol as well as bradykinin, which tended to potentiate, but not significantly, inhibition of the fenoterol-induced sensitization by the NK 1 , NK 2 , and NK 3 receptor antagonists. In the absence of incubation with fenoterol, we found that tachykinins and bradykinin were not involved in the process of contraction to ET-1 and ACh. Additional studies are needed to clarify the role of tachykinins and bradykinin in the contraction mechanisms after sensitization by fenoterol in human bronchi.
Studies in animal and human airways have shown that the epithelial ET A receptor may mediate NO production (via the constitutive NOS) and prostaglandin E 2 production (via the epithelial COX-2) (3, 8, 31, 44) . Epithelial NO and prostaglandin E 2 are relaxant for the airway smooth muscle. In a recent study, Naline and colleagues (44) found that NO is the major determinant of the epithelial regulation of the human airway smooth muscle contraction to ET-1. Our results are in agreement with these authors, because we showed that L-NAME, but not indomethacin and GR-32191, enhanced the contractility to ET-1. The epithelial regulation of the contractility to ACh was also mediated by NO. On the contrary, after sensitization by fenoterol, L-NAME failed to enhance the maximal contractility to ET-1 and ACh. We suggest that chronic exposure to fenoterol induces a disruption of the epithelial regulation of the airway smooth muscle contraction to ET-1 and ACh. Further investigations are needed to confirm and elucidate this mechanism.
Our study has several limitations. First, we studied bronchi obtained from nonhealthy subjects, who were all previous smokers. ⌬E max was increased by fenoterol exposure in only 38 of 48 bronchi. ␤ 2 -Adrenoceptor polymorphisms inducing variable response to ␤ 2 -agonists may constitute a possible explanation of this fickle sensitizing effect (55) . For instance, the Gly 16 ␤ 2 -adrenoceptor polymorphism could be associated with asthma severity (37) . However, in patients treated chronically with salmeterol, exacerbations are not correlated with the Gly 16 polymorphism (56). The ␤ 2 -agonist concentrations that we used to sensitize the bronchi may not be consistent with the in vivo concentrations obtained by actual treatment using ␤ 2 -agonists. In a randomized study comparing clinical efficacy of nebulized vs. intravenous salbutamol in severe acute asthma, Salmeron and colleagues (51) found plasma concentrations of salbutamol on the order of 10 Ϫ5 M. In healthy volunteers, plasma formoterol concentration reached 10 Ϫ9 M after inhalation of a single dose of 120 g of formoterol fumarate (40) . Therapeutic plasma concentration of fenoterol of ϳ10 Ϫ8 M was recommended (18) , but plasma concentration associated with serious toxicity is not known.
In summary, our study demonstrates the proinflammatory effects of chronic exposure to ␤ 2 -agonists in human bronchus. Our results suggest that these proinflammatory effects are mediated by NF-B and lead to sensitization of airway smooth muscle. MAPK, PKC, and tachykinins seem to play a major role in the sensitization of the human bronchus after chronic exposure to ␤ 2 -adrenergic agents.
